Research ExplorerPublicationsImmunology of pregnancy and reproductive health in autoimmun...

Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases

Standard

Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases. / Andreoli, Laura; Chighizola, Cecilia B; Iaccarino, Luca; Botta, Angela; Gerosa, Maria; Ramoni, Véronique; Tani, Chiara; Bermas, Bonnie; Brucato, Antonio; Buyon, Jill; Cetin, Irene; Chambers, Christina D; Clowse, Megan E B; Costedoat-Chalumeau, Nathalie; Cutolo, Maurizio; De Carolis, Sara; Dolhain, Radboud; Fazzi, Elisa M; Förger, Frauke; Giles, Ian; Haase, Isabell; Khamashta, Munther; Levy, Roger A; Meroni, Pier Luigi; Mosca, Marta; Nelson-Piercy, Catherine; Raio, Luigi; Salmon, Jane; Villiger, Peter; Wahren-Herlenius, Marie; Wallenius, Marianne; Zanardini, Cristina; Shoenfeld, Yehuda; Tincani, Angela.

In: AUTOIMMUN REV, Vol. 22, No. 3, 03.2023, p. 103259.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Andreoli, L, Chighizola, CB, Iaccarino, L, Botta, A, Gerosa, M, Ramoni, V, Tani, C, Bermas, B, Brucato, A, Buyon, J, Cetin, I, Chambers, CD, Clowse, MEB, Costedoat-Chalumeau, N, Cutolo, M, De Carolis, S, Dolhain, R, Fazzi, EM, Förger, F, Giles, I, Haase, I, Khamashta, M, Levy, RA, Meroni, PL, Mosca, M, Nelson-Piercy, C, Raio, L, Salmon, J, Villiger, P, Wahren-Herlenius, M, Wallenius, M, Zanardini, C, Shoenfeld, Y & Tincani, A 2023, 'Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases', AUTOIMMUN REV, vol. 22, no. 3, pp. 103259. https://doi.org/10.1016/j.autrev.2022.103259

APA

Andreoli, L., Chighizola, C. B., Iaccarino, L., Botta, A., Gerosa, M., Ramoni, V., Tani, C., Bermas, B., Brucato, A., Buyon, J., Cetin, I., Chambers, C. D., Clowse, M. E. B., Costedoat-Chalumeau, N., Cutolo, M., De Carolis, S., Dolhain, R., Fazzi, E. M., Förger, F., ... Tincani, A. (2023). Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases. AUTOIMMUN REV, 22(3), 103259. https://doi.org/10.1016/j.autrev.2022.103259

Vancouver

Andreoli L, Chighizola CB, Iaccarino L, Botta A, Gerosa M, Ramoni V et al. Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases. AUTOIMMUN REV. 2023 Mar;22(3):103259. https://doi.org/10.1016/j.autrev.2022.103259

Bibtex

@article{c9c0c4c7253f4b2cac1fc5afb15904f9,
title = "Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases",
abstract = "Autoimmune rheumatic diseases (ARD) can affect women and men during fertile age, therefore reproductive health is a priority issue in rheumatology. Many topics need to be considered during preconception counselling: fertility, the impact of disease-related factors on pregnancy outcomes, the influence of pregnancy on disease activity, the compatibility of medications with pregnancy and breastfeeding. Risk stratification and individualized treatment approach elaborated by a multidisciplinary team minimize the risk of adverse pregnancy outcomes (APO). Research has been focused on identifying biomarkers that can be predictive of APO. Specifically, preeclampsia and hypertensive disorders of pregnancy tend to develop more frequently in women with ARD. Placental insufficiency can lead to intrauterine growth restriction and small-for-gestational age newborns. Such APO have been shown to be associated with maternal disease activity in different ARD. Therefore, a key message to be addressed to the woman wishing for a pregnancy and to her family is that treatment with compatible drugs is the best way to ensure maternal and fetal wellbeing. An increasing number of medications have entered the management of ARD, but data about their use in pregnancy and lactation are scarce. More information is needed for most biologic drugs and their biosimilars, and for the so-called small molecules, while there is sufficient evidence to recommend the use of TNF inhibitors if needed for keeping maternal disease under control. Other issues related to the reproductive journey have emerged as {"}unmet needs{"}, such as sexual dysfunction, contraception, medically assisted reproduction techniques, long-term outcome of children, and they will be addressed in this review paper. Collaborative research has been instrumental to reach current knowledge and the future will bring novel insights thanks to pregnancy registries and prospective studies that have been established in several Countries and to their joint efforts in merging data.",
keywords = "Male, Child, Pregnancy, Female, Infant, Newborn, Humans, Prospective Studies, Reproductive Health, Biosimilar Pharmaceuticals, Placenta, Pregnancy Outcome, Autoimmune Diseases/complications, Rheumatic Diseases/complications",
author = "Laura Andreoli and Chighizola, {Cecilia B} and Luca Iaccarino and Angela Botta and Maria Gerosa and V{\'e}ronique Ramoni and Chiara Tani and Bonnie Bermas and Antonio Brucato and Jill Buyon and Irene Cetin and Chambers, {Christina D} and Clowse, {Megan E B} and Nathalie Costedoat-Chalumeau and Maurizio Cutolo and {De Carolis}, Sara and Radboud Dolhain and Fazzi, {Elisa M} and Frauke F{\"o}rger and Ian Giles and Isabell Haase and Munther Khamashta and Levy, {Roger A} and Meroni, {Pier Luigi} and Marta Mosca and Catherine Nelson-Piercy and Luigi Raio and Jane Salmon and Peter Villiger and Marie Wahren-Herlenius and Marianne Wallenius and Cristina Zanardini and Yehuda Shoenfeld and Angela Tincani",
note = "Copyright {\textcopyright} 2022 Elsevier B.V. All rights reserved.",
year = "2023",
month = mar,
doi = "10.1016/j.autrev.2022.103259",
language = "English",
volume = "22",
pages = "103259",
journal = "AUTOIMMUN REV",
issn = "1568-9972",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases

AU - Andreoli, Laura

AU - Chighizola, Cecilia B

AU - Iaccarino, Luca

AU - Botta, Angela

AU - Gerosa, Maria

AU - Ramoni, Véronique

AU - Tani, Chiara

AU - Bermas, Bonnie

AU - Brucato, Antonio

AU - Buyon, Jill

AU - Cetin, Irene

AU - Chambers, Christina D

AU - Clowse, Megan E B

AU - Costedoat-Chalumeau, Nathalie

AU - Cutolo, Maurizio

AU - De Carolis, Sara

AU - Dolhain, Radboud

AU - Fazzi, Elisa M

AU - Förger, Frauke

AU - Giles, Ian

AU - Haase, Isabell

AU - Khamashta, Munther

AU - Levy, Roger A

AU - Meroni, Pier Luigi

AU - Mosca, Marta

AU - Nelson-Piercy, Catherine

AU - Raio, Luigi

AU - Salmon, Jane

AU - Villiger, Peter

AU - Wahren-Herlenius, Marie

AU - Wallenius, Marianne

AU - Zanardini, Cristina

AU - Shoenfeld, Yehuda

AU - Tincani, Angela

N1 - Copyright © 2022 Elsevier B.V. All rights reserved.

PY - 2023/3

Y1 - 2023/3

N2 - Autoimmune rheumatic diseases (ARD) can affect women and men during fertile age, therefore reproductive health is a priority issue in rheumatology. Many topics need to be considered during preconception counselling: fertility, the impact of disease-related factors on pregnancy outcomes, the influence of pregnancy on disease activity, the compatibility of medications with pregnancy and breastfeeding. Risk stratification and individualized treatment approach elaborated by a multidisciplinary team minimize the risk of adverse pregnancy outcomes (APO). Research has been focused on identifying biomarkers that can be predictive of APO. Specifically, preeclampsia and hypertensive disorders of pregnancy tend to develop more frequently in women with ARD. Placental insufficiency can lead to intrauterine growth restriction and small-for-gestational age newborns. Such APO have been shown to be associated with maternal disease activity in different ARD. Therefore, a key message to be addressed to the woman wishing for a pregnancy and to her family is that treatment with compatible drugs is the best way to ensure maternal and fetal wellbeing. An increasing number of medications have entered the management of ARD, but data about their use in pregnancy and lactation are scarce. More information is needed for most biologic drugs and their biosimilars, and for the so-called small molecules, while there is sufficient evidence to recommend the use of TNF inhibitors if needed for keeping maternal disease under control. Other issues related to the reproductive journey have emerged as "unmet needs", such as sexual dysfunction, contraception, medically assisted reproduction techniques, long-term outcome of children, and they will be addressed in this review paper. Collaborative research has been instrumental to reach current knowledge and the future will bring novel insights thanks to pregnancy registries and prospective studies that have been established in several Countries and to their joint efforts in merging data.

AB - Autoimmune rheumatic diseases (ARD) can affect women and men during fertile age, therefore reproductive health is a priority issue in rheumatology. Many topics need to be considered during preconception counselling: fertility, the impact of disease-related factors on pregnancy outcomes, the influence of pregnancy on disease activity, the compatibility of medications with pregnancy and breastfeeding. Risk stratification and individualized treatment approach elaborated by a multidisciplinary team minimize the risk of adverse pregnancy outcomes (APO). Research has been focused on identifying biomarkers that can be predictive of APO. Specifically, preeclampsia and hypertensive disorders of pregnancy tend to develop more frequently in women with ARD. Placental insufficiency can lead to intrauterine growth restriction and small-for-gestational age newborns. Such APO have been shown to be associated with maternal disease activity in different ARD. Therefore, a key message to be addressed to the woman wishing for a pregnancy and to her family is that treatment with compatible drugs is the best way to ensure maternal and fetal wellbeing. An increasing number of medications have entered the management of ARD, but data about their use in pregnancy and lactation are scarce. More information is needed for most biologic drugs and their biosimilars, and for the so-called small molecules, while there is sufficient evidence to recommend the use of TNF inhibitors if needed for keeping maternal disease under control. Other issues related to the reproductive journey have emerged as "unmet needs", such as sexual dysfunction, contraception, medically assisted reproduction techniques, long-term outcome of children, and they will be addressed in this review paper. Collaborative research has been instrumental to reach current knowledge and the future will bring novel insights thanks to pregnancy registries and prospective studies that have been established in several Countries and to their joint efforts in merging data.

KW - Male

KW - Child

KW - Pregnancy

KW - Female

KW - Infant, Newborn

KW - Humans

KW - Prospective Studies

KW - Reproductive Health

KW - Biosimilar Pharmaceuticals

KW - Placenta

KW - Pregnancy Outcome

KW - Autoimmune Diseases/complications

KW - Rheumatic Diseases/complications

U2 - 10.1016/j.autrev.2022.103259

DO - 10.1016/j.autrev.2022.103259

M3 - SCORING: Review article

C2 - 36549355

VL - 22

SP - 103259

JO - AUTOIMMUN REV

JF - AUTOIMMUN REV

SN - 1568-9972

IS - 3

ER -